OvariAn Secretome and Integrated HealthSpan (OASIS)
A Three-Part Study of Ovarian Aging, Circulating Molecular Signatures, and Multidomain Healthspan in Women
The OASIS study aims to identify and characterize circulating molecular signatures associated with ovarian aging, and to determine how these signatures relate to multidomain healthspan during the menopausal transition. The study consists of three parts. Part 1 is a retrospective analysis of existing clinical data and stored biospecimens from approximately 500 women aged 50-85 years. Part 2 is a prospective cohort of 300 women aged 40-50 years who will undergo comprehensive clinical, gynecological, and molecular assessments over 24 months, followed by individualized medical management based on their clinical findings. Part 3 (PRISM) is a nested substudy involving up to 30 women from the prospective cohort who will undergo intensive hormonal and ultrasound monitoring across a single menstrual cycle.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Background and Purpose:
The menopausal transition is a biologically dynamic period involving changes in ovarian reserve, endocrine function, and morphology that parallel shifts in body composition, bone, cardiovascular, metabolic, sleep, and cognitive health. Because conventional endocrine markers (estradiol, FSH, LH, AMH) do not provide a complete molecular readout of ovarian biology across this transition, OASIS will establish an integrated biological framework linking ovarian aging with systemic molecular physiology using advanced multi-omics profiling.
Part 1: Retrospective OASIS Biobank Cohort This phase includes approximately 500 women aged 50-85 years who previously participated in research at Sheba Medical Center and signed the applicable Biobank consent. The study utilizes existing coded demographic, clinical, and lifestyle data, alongside stored plasma samples. No new patient contact or procedures are required.
Part 2: Prospective OASIS Cohort
This phase will enroll 300 women aged 40-50 years. Participants will complete three study visits over two years:
Baseline (Month 0) and Month 12: Comprehensive multidomain clinical assessment, standardized gynecological evaluation, transvaginal ultrasound (uterus and ovaries), and biospecimen collection for clinical testing and biospecimen banking.
Month 24: A limited follow-up visit including a medical update, the Menopause Rating Scale (MRS) and selected questionnaires, fasting reproductive-hormone testing (including AMH), biospecimen collection, and a gynecological/ultrasound assessment.
Clinical Management: Following the baseline visit, participants will receive their validated clinical results, a medical summary, and individualized recommendations. Management is tailored to the participant's specific clinical findings and may include lifestyle modifications and consideration of Hormone Replacement Therapy/Menopausal Hormone Therapy (HRT/MHT) when clinically indicated.
Part 3: PRISM Nested Intensive Substudy (Precision Reproductive Imaging and Secretome Monitoring) Participation in PRISM is optional and requires separate informed consent. Up to 30 women from Part 2 may participate in up to four additional visits, separate from the main OASIS baseline visit, during a single menstrual cycle.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Abigail Goshen, PhD
- Phone Number: 972542270050
- Email: Abigail.Goshen@sheba.health.gov.il
Study Locations
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Israel, 5262000
- Sheba Medical Center
-
Contact:
- Abigail Goshen
- Phone Number: 972542270050
-
Principal Investigator:
- Abigail Goshen, PhD
-
Principal Investigator:
- Lauren Petrick, PhD
-
Sub-Investigator:
- Yaron Rabinovici, Dr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Part 1, retrospective biobank cohort: women aged 50 years and above Parts 2 and 3, prospective main cohort and nested PRISM cohort: women aged 40-50 years
Description
Inclusion Criteria:
- Women aged 50-85 years at enrollment (for part 1 retrospective study). or
- Women aged 40-50 years at enrollment (for part 2 prospective study).
- Able to understand the study information and provide written informed consent.
- Able and willing to complete the study assessments and follow-up visits.
Part 3 (PRISM substudy) specific criteria:
- Natural, regular menstruation.
- Reported menstrual-cycle length of 21-35 days.
- Willing and able to attend four additional blood-draw and transvaginal ultrasound visits across one menstrual cycle.
- Signed separate PRISM informed consent.
- Not using oral contraceptives, other hormonal contraceptives, menopausal hormone therapy, or another hormonal treatment at PRISM enrollment.
Exclusion Criteria:
- A former diagnosis of significant cognitive reduction (MoCA score <24).
- Former diagnosis of a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, or Lewy body dementia.
- Former diagnosis of psychiatric disease.
- Underwent chemotherapy or radiation therapy in the past two years.
Part 3 (PRISM substudy) specific criteria:
- Failure to meet the PRISM inclusion criteria.
- Unwillingness or inability to sign the PRISM consent.
- Irregular cycle or reported cycle length outside 21-35 days.
- Current hormonal contraceptive, menopausal hormone therapy or other hormonal treatment.
- Inability or unwillingness to undergo repeated blood draws.
- Inability or unwillingness to undergo transvaginal ultrasound.
- A medical condition that, in the investigator's judgment, makes participation unsafe or unsuitable.
- A medical, technical, or logistical reason that precludes reliable completion of the substudy.
- Pregnancy, breastfeeding, initiation of hormonal treatment, or a significant medical change during PRISM must be reported to the study team and may lead to discontinuation at the Principal Investigator's discretion.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: OTHER
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Part 1: Retrospective Biobank Cohort
500 women aged 50 years and older with available clinical data and stored biospecimens from the Sheba Biobank. Evaluation is limited to retrospective data extraction and molecular analysis. |
|
Part 2: Prospective Main Cohort
300 women aged 40-50 years undergo longitudinal clinical, multidomain, and gynecological assessments at Baseline, Month 12, and Month 24, and provide biosamples. Participants receive individualized clinical management (including potential HRT/MHT) based on the clinical findings. |
|
Part 3: PRISM Nested Substudy
Up to 30 women co-enrolled from Part 2. Participants undergo intensive repeated measures (transvaginal ultrasound and blood sampling for hormone/molecular analysis) across up to four visits during a single menstrual cycle to assess short-term longitudinal changes. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reproductive hormone concentrations
Time Frame: Baseline, 12 months, 24 months
|
The concentrations of anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and progesterone will be measured in blood samples. |
Baseline, 12 months, 24 months
|
|
Antral Follicle Count (AFC)
Time Frame: Baseline, 12 months, 24 months
|
The total number of antral follicles in both ovaries will be assessed using transvaginal ultrasound. |
Baseline, 12 months, 24 months
|
|
Total ovarian volume
Time Frame: Baseline, 12 months, 24 months
|
Ovarian volume in milliliters will be measured using transvaginal ultrasound. Total ovarian volume will be calculated based on measurements of both ovaries. |
Baseline, 12 months, 24 months
|
|
Number of participants with abnormal ovarian or adnexal ultrasound findings
Time Frame: Baseline, 12 months, 24 months
|
The number and proportion of participants with abnormal ovarian morphology, ovarian cysts, or other abnormal adnexal findings identified by transvaginal ultrasound will be recorded. |
Baseline, 12 months, 24 months
|
|
Circulating ovarian-associated molecular signature
Time Frame: Baseline, 12 months
|
Plasma protein levels will be assessed using high-throughput proteomic profiling with the Olink Explore HT platform to characterize circulating molecular signatures associated with ovarian function. |
Baseline, 12 months
|
|
Montreal Cognitive Assessment (MoCA) score
Time Frame: Baseline, 12 months
|
Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The total score ranges from 0 to 30, with higher scores indicating better cognitive performance. |
Baseline, 12 months
|
|
Apnea-Hypopnea Index (AHI)
Time Frame: Baseline, 12 months
|
Sleep apnea severity will be assessed by measuring the Apnea-Hypopnea Index (AHI), defined as the number of apnea and hypopnea events per hour of sleep. |
Baseline, 12 months
|
|
Glycated hemoglobin (HbA1c)
Time Frame: Baseline, 12 months
|
Glycemic control will be assessed by measuring the percentage of glycated hemoglobin (HbA1c) in blood samples. |
Baseline, 12 months
|
|
DXA-derived body composition
Time Frame: Baseline, 12 months
|
Body composition will be assessed using dual-energy X-ray absorptiometry (DXA), including measurements of fat mass and lean mass (kg). |
Baseline, 12 months
|
|
Bone mineral density (BMD)
Time Frame: Baseline, 12 months
|
Bone mineral density (BMD) will be measured using dual-energy X-ray absorptiometry (DXA) at the lumbar spine, femoral neck, and total hip. Results will be reported in g/cm². |
Baseline, 12 months
|
|
Handgrip strength
Time Frame: Baseline, 12 months
|
Physical function will be assessed by measuring handgrip strength using a calibrated hand dynamometer. Results will be reported in kilograms (kg). |
Baseline, 12 months
|
|
Pulse wave velocity (PWV)
Time Frame: Baseline, 12 months
|
Arterial stiffness will be assessed by measuring pulse wave velocity (PWV). Results will be reported in meters per second (m/s). |
Baseline, 12 months
|
|
Within-woman changes in reproductive endocrine measures
Time Frame: Up to four sampling time points during the first month of the study
|
Serial measurements of AMH, FSH, LH, estradiol, and progesterone concentrations in blood samples will be performed to assess short-term hormonal fluctuations within participants. |
Up to four sampling time points during the first month of the study
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Abigail Goshen, PhD, Sheba Medical Center
Publications and helpful links
General Publications
- Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012 Apr;19(4):387-95. doi: 10.1097/gme.0b013e31824d8f40.
- Moolhuijsen LME, Visser JA. Anti-Mullerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab. 2020 Nov 1;105(11):3361-73. doi: 10.1210/clinem/dgaa513.
- Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org; Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020 Dec;114(6):1151-1157. doi: 10.1016/j.fertnstert.2020.09.134.
- Greendale GA, Huang MH, Wight RG, Seeman T, Luetters C, Avis NE, Johnston J, Karlamangla AS. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009 May 26;72(21):1850-7. doi: 10.1212/WNL.0b013e3181a71193.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 3577-26-SMC
- OD-2026001 (Other Grant/Funding Number: Nuttall Women's Health (NWH))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.